Compare TWIN & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | GBIO |
|---|---|---|
| Founded | 1918 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | TWIN | GBIO |
|---|---|---|
| Price | $15.45 | $5.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $8.88 |
| AVG Volume (30 Days) | 24.5K | ★ 51.7K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $347,837,000.00 | $15,270,000.00 |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $640.74 | ★ N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $6.16 | $3.00 |
| 52 Week High | $17.08 | $12.50 |
| Indicator | TWIN | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 53.08 |
| Support Level | $15.28 | $5.20 |
| Resistance Level | $15.84 | $5.54 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 34.52 | 69.49 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.